Results 161 to 170 of about 122,434 (251)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Artificial intelligence-based quantification of retinal microvascular biomarkers from fundus photography of chronic kidney disease: a case-control study. [PDF]

Front Med (Lausanne)
Gu Q, Liu M, Zhang W, Chen Z, Wang X, Wang J, He Z, Lu F.   +7 more
europepmc   +1 more source

Drug Critical Limits for Urgent Physician Notification

Clinical Pharmacology &Therapeutics, EarlyView.
Critical limits represent quantitative decision thresholds for drugs that require immediate clinician notification and potential life‐saving intervention. United States hospitals lack a national standard for drug critical limits. We collected critical limits from 417 US hospitals across all 50 states and Washington, D.C.; of these, 411 maintained drug ...
Elina Kuang, Yasmeen Ibrahim, Kyle Cheng, Gerald J. Kost   +3 more
wiley   +1 more source

Molecular characterization of Cdh12-SCON conditional knockout mice reveals unexpected splicing changes. [PDF]

Transgenic Res
Ten Hoor MAC, Linssen MM, Brouwers CM, Claassens JWC, Mulder J, Hohenstein P.   +5 more
europepmc   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board. [PDF]

Clin Kidney J
Kanbay M, Copur S, Capasso G, Turkmen K, Delanaye P, Bruchfeld A, Abd ElHafeez S, Ferro CJ, Verhaar MC, Pesce F, Liakopoulos V, Boor P, Adamczak M, Vivarelli M, Navarro-González JF, Kramann R, Florquin S, Valdieso JM.   +17 more
europepmc   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

Explainable AI in kidney stone detection and segmentation: a mini review. [PDF]

Front Digit Health
Hossen MJ, Haque BMT, Bannah H, Rahman MA, Ahmed A, Noman AA.   +5 more
europepmc   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source